,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04']
just arrived home from #asco22 and still not over some of the presentations we witnessed. in particular, destiny-04: t-dxd for hr+/- her2low hormone resistant metastatic bc and how it significantly improved both pfs &amp; os. absolutely life changing for so many women 
Clinical Cancer researcher????????? cat mom ?? musical lover ?? book worm ?? womens health advocate ??Swiftie ??????? Views my own